As of 2026-09-27, the Relative Valuation of TCR2 Therapeutics Inc (TCRR) is (89.42) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.48 USD, the upside of TCR2 Therapeutics Inc based on Relative Valuation is -6141.8%.
The range of the Relative Valuation is (79.34) - (106.35) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.1x - 25.6x | 22.4x |
| Forward P/E multiples | 15.7x - 25.7x | 20.7x |
| Fair Price | (79.34) - (106.35) | (89.42) |
| Upside | -5461.1% - -7285.6% | -6141.8% |
| Date | P/E |